|
|
Article: One less treatment for bedwetting.(Brief article)
- Article from:
- Pediatrics for Parents
- Article date:
- May 1, 2008
CopyrightCOPYRIGHT 2008 Pediatrics for Parents, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Last December, the Food and Drug Administration (FDA) warned healthcare professionals about using desmopressin to treat primary nocturnal enuresis (PNE, or bedwetting). The drug, a popular bedwetting treatment, poses a significant risk for severe hyponatremia (low blood sodium level), which can cause seizures and even death.
A review of 61 post-marketing studies found that desmopressin, sold as DDAVP, Minirin, and Stimate, caused a number of cases of hyponatremia-related seizures. The nasal spray form of desmopressin has been banned, and although the tablet form still has many other uses and can be prescribed for primary nocturnal enuresis, it should be stopped ...